[A21-17] Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 03.05.2021
Commission awarded on 02.03.2021 by the Federal Joint Committee (G-BA).
Maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy
Hint of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-88||Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|G17-15||Niraparib (ovarian cancer) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V||Commission completed|
|A20-98||Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|